Background: The association between depression and immune response is not yet clear. The biological mechanisms by which depression alters the immune system is not yet understood. The purpose of this study was to investigate the longitudinal relationship between depressive symptoms and cellular immune response. Methods: A cohort study with a baseline measurement and three annual health assessments was set up in a residential home for elderly people in Rome, Italy. A total of 166 residents aged 65 years and older, mean age 81 years, were interviewed and blood samples were collected at each annual assessment. Percentage changes in lymphocytes and T-cell subsets related to depressive symptoms were estimated over a period of 4 years, using regression models for repeated measurements. Results: Elderly people with seven or more symptoms of depression, according to the Geriatric Depression Scale, had a lower percentage of CD4+DR+ T-cells over 4 years [β = –20.2; 95% confidence interval (CI) = –33.0 to –4.9] and CD8+DR+ T-cells (β = –26.9; 95% CI = –42.5 to –7.0) than elderly with less than seven symptoms of depression, after adjusting for confounding factors (sex, age, marital status, education, smoking habit, nutritional status, chronic diseases, disability and the use of benzodiazepines). Conclusion: The results of this study suggest an adverse effect of depressive symptoms on immune response. It remains to be determined whether these depression-associated immune changes are related to the onset or course of physical illness and the increased mortality observed in depressed old people.

Keywords:
Depression, Immunity, Elderly population, T-cells
1.
Beekman ATF, Copeland JRM, Prince MJ: Review of community prevalence of depression in late life. Br J Psychiatry 1999;174:307–311.
2.
Livingston G, Watkin V, Milne B, Manela M, Katona C: The natural history of depression and the anxiety disorders in older people. J Affect Disord 1997;46:255–262.
3.
Murphy E, Smith R, Lindesay J, Slattery J: Increased mortality rates in late-life depression. Br J Psychiatry 1988;152:347–353.
4.
Barefoot JC, Schroll M: Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996;93:1976–1980.
5.
Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaten WW: Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 1996;94:3123–3129.
6.
Whooley MA, Browner WS: Association between depressive symptoms and mortality in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1998;158:2129–2135.
7.
Herbert TB, Cohen S: Depression and immunity: A meta-analysis review. Psychol Bull 1993;113:472–486.
8.
Calabrese JR, Kling MA, Gold PW: Alterations in immunocompetence during stress, bereavement and depression: Focus on neuroendocrine regulation. Am J Psychiatry 1987;144:1123–1134.
9.
Muller N, Ackenheil M: Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:1–33.
10.
Stein RL: Depression and the immune system; in Ader R, Felten DL, Cohen N (eds): Psychoneuroimmunology, ed 2. London, Academic Press, 1991, pp 897–929.
11.
Bauer ME, Gauer GJ, Luz C, Silveira RO, Nardi NB, Von Muhlen CA: Evaluation of immune parameters in depressed patients. Life Sci 1995;57:665–674.
12.
Hickie I, Hichie C, Loyd A, Silove D, Wakefield D: Impaired in vivo immune responses in patients with melancholia. Br J Psychiatry 1993;162:651–657.
13.
Hickie I, Hickie C, Bennet B, Wakefield D, Silove D, Mitchell P, Loyd A: Biochemical correlates of in vivo cell-mediated immune dysfunction in patients with depression: A preliminary report. Int J Immunopharmacol 1995;19:685–690.
14.
Fortes C, Forastiere F, Farchi S, Rapiti E, Pastori G, Perucci CA: Diet and overall survival in a very old cohort of elderly. Epidemiology 2000;11:440–445.
15.
The Royal College of Physicians of London and the British Geriatrics Society: Standardised Assessment Scales for Elderly People: A Report of Joint Workshops of the Research Unit of the Royal College of Physicians and the British Geriatric Society. London, Royal College of Physicians of London Editors, 1992, pp 6–15.
16.
Almeida OP, Almeida SA: Short versions of the geriatric depression scale: A study of their validity for the diagnosis of a major depressive episode to ICD-10 and DSM-IV. Int J Geriatr Psychiatry 1999;14:858–865.
17.
Osborn DP, Fletcher AE, Smeeth L, Stirling S, Nunes M, Breeze E, Siu-Woon NGE, Bulpitt CJ, Jones D, Tulloch A, Siu-Woon E: Geriatric Depression Scale Scores in a representative sample of 14,545 people aged 75 and over in the United Kingdom: Results from the MRC Trial of Assessment and Management of Older People in the Community. Int J Geriatr Psychiatry 2002;17:375–382.
18.
Lohman T, Roche AF, Martorell R: Anthropometric Standardisation Reference Manual. Champaign, Human Kinetics Books, 1988.
19.
Pacifici R, Zuccaro P, Cozzi-Lepre A, Di Carlo S, Bacosi A, Fattorossi A: Quantification of the variation due to lysing technique in immunophenotyping of healthy and HIV-infected individuals. Clin Biochem 1998;31:165–172.
20.
Kutok JL, Roma AO, Lemire SJ, Dorfman DM: Four-color flow cytometric immunophanotypic determination of peripheral blood CD4+ T-lymphocyte counts: A comparison of validity and cost-effectiveness with a two-color method. Am J Clin Pathol 1998;110:465–470.
21.
Zeger SL, Liang KY: An overview of methods for the analysis of longitudinal data. Stat Med 1992;11:1825–1839.
22.
StataCorp: Stata Statistical Software: Release 5.0. College Station. Stata Corporation, 1997.
23.
Lesourd BM, Laisney C, Salvatore R, Meaume S, Moulias R: Decreased maturation of T-cell population in the healthy elderly: Influence of nutritional factors on the appearance of double negative CD4–, CD8–, CD2+ cells. Arch Gerontol Geriatr 1994,4:139–154.
24.
Johnson JD, Hounchins DP, Kluwe WM, Craig KD, Fischer GL: Effects of mainstream and environmental tobacco smoke on the immune system in animals and humans: A review. Crit Rev Toxicol 1990;29:369–395.
25.
Remarque EJ, Cools HJM, Boere TJ, Van der Klis RJ, Masurel N, Litgthart GJ: Functional disability and antibody response to influenza vaccine in elderly patients in a Dutch nursing population. BMJ 1996;312:1015.
26.
Zavala F: Benzodiazepines, anxiety and immunity. Pharmacol Ther 1997;75:199–216.
27.
Savard J, Miller S, Megan M, O’Leary A, Harding H, Douglas SD, Mangan CE, Belch R, Winokur A: Association between subjective sleep quality and depression on immunocompetence in low-income women at risk for cervical cancer. Psychosom Med 1999;61:496–507.
28.
Maes M: Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999;461:25–46.
29.
Schleifer SJ, Bartlett JA, Keller SE, Eckholdt HM, Shiflett SC, Delaney BR: Immunity in adolescents with major depression. J Am Acad Child Adolesc Psychiatry 2002;41:1054–1060.
30.
Terpenning MS, Bradley SFB: Why aging leads to increased susceptibility to infection. Geriatrics 1991;46:7780.
31.
Hanson LC, Weber DJ, Rutala W: Risk factors for nosocomial pneumonia in the elderly. Am J Med 1992;92:161–166.
32.
Brostoff J, Scadding GK, Male D, Roitt IM: Principles of immunity to infection; in Brostoff J, Scadding GK, Male D, Roitt IM (eds): Clinical Immunology. London, Gower Medical Publishing, 1991, pp 22.4–22.6.
33.
Wybran J: Enkephalins and endorphins as modifiers of the immune system: Present and future. Fed Proc 1985;44:92–94.
34.
Shinkawa M, Yanai M, Yamaya M, Sasaki H: Depressive state and common cold. Lancet 2000;356:942–946.
35.
Ader R, Cohen N, Felten D: Psychoneuroimmunology: Interactions between the nervous system and the immune system. Lancet 1995;345:99–103.
36.
Nerozzi D, Santoni A, Bersani G, Magnani A, Bressan A, Pasini A, Antonozzi I, Frajese G: Reduced natural killer cell activity in major depression: Neuroendocrine implications. Psychoneuroendocrinology 1989;14:295–301.
37.
Buckingham JC, Gillies GE, Cowell AM (eds): Stress, Stress Hormones and the Immune Response System. Chichester, Wiley, 1997.
38.
Benschop RJ, Nieuwenhius EES, Tromp EAM: Effects of beta-adrenergic blockade on immunologic and cardiovascular changes induced by mental stress. Circulation 1994;89:762–769.
39.
Robert-Thompson IC, Whittingham S, Younghaiyd U, Mackay IR: Ageing, immune response and mortality. Lancet 1974;17:368–370.
40.
Cohn JR, Hohl CA, Buckley E: The relationship between cutaneous cellular immune responsiveness and mortality in a nursing home population. J Am Geriatr Soc 1983;31:808–809.
41.
Wayne S, Rhyne RL, Garry P, Goodwin JS: Cell-mediated immunity as a predictor of morbidity and mortality in subjects over 60. J Gerontol 1990;45:45–48.
42.
Fergunson FG, Wikby A, Maxson P, Olsson J, Johansson B: Immune parameters in a longitudinal study of a very old population of Swedish people: A comparison between survivors and nonsurvivors. J Gerontol A Biol Sci Med Sci 1995;50:378–382.
43.
Lange GL, Schreiner GF: Immune mechanisms of cardiac disease. N Engl J Med 1994;330:1129–1135.
44.
Hippisley-Cox J, Fielding K, Pringle M: Depression as a risk factor for ischaemic heart disease in men: Population base case-control. BMJ 1998;316:1714–1719.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.